Fujitsu Launches Solution Which Supports Cloud-based Epic EPRs
Fujitsu has launched a solution which will allow NHS trusts and other healthcare organisations in the UK to host their Epic electronic patient record (EPR) in the cloud.
This means that for the first time, healthcare organisations looking to deploy Epic have the option to run the electronic patient record (EPR) in the cloud via Fujitsu’s Epic in the Cloud.
The solution is designed to help address challenges that NHS trusts and UK healthcare organisations can face in making the business case for Epic and then deploying and consuming upgrades for the EPR.
The infrastructure is evergreen, meaning Epic upgrades can be easily tested and deployed, removing the need for unplanned technology investments or regular infrastructure refreshes. Healthcare organisations can therefore focus their time and resources on accelerating their digital maturity and broader data strategies.
Matthew Chase, healthcare chief technology officer, Fujitsu UK, and former deputy chief technology officer at Guy’s and St Thomas’ NHS Foundation Trust, said: “Until now, trusts that wanted to run Epic had to create the infrastructure to host it on-premises or work with a third-party hosting service.
“Now, they have the option to have Fujitsu host it for them on AWS. That means trusts can look to get the resilience and flexibility of cloud computing, the benefits of Epic, and the support they need from Fujitsu and its partners to generate the cost savings and clinical benefits they expect, faster.”
Fujitsu in the UK has introduced Epic in the Cloud in support for the Amazon Web Services (AWS) for Health initiative which has been designed to make it easier for health professionals to select the right tools, partners and industry specialists to address their highest-priority workloads across the healthcare community.
People In This Post
Companies In This Post
- Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Read more
- iCRYO Announces Partnership with Therapeutic Manufacturer, BTL Read more
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis Read more
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease Read more
- Poseida Therapeutics Announces Board Change Read more